Please see disclaimer at the foot of the press release
Wednesday, 19 November 2014
AstraZeneca PLC, rated A2 (stable outlook) by Moody's and AA- (negative outlook) by Standard & Poor's, announces today the successful pricing of euro medium term notes in an aggregate principal amount of €750,000,000 maturing on 24 November 2021 with a coupon of 0.875% (the “Notes”).
The proceeds of the issue will be used to fund the repayment of outstanding euro medium term notes in an aggregate principal amount of €750,000,000 maturing in January 2015.
The Notes are being issued under the U.S.$5,000,000,000 Euro Medium Term Note Programme of AstraZeneca PLC.
The Notes will be issued to institutional investors outside the US in accordance with Regulation S of the U.S. Securities Act of 1933, as amended. The Notes will be admitted to listing on the UK Listing Authority's Official List and to trading on the London Stock Exchange's regulated market.
NOTES FOR EDITORS
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
|Esra Erkal-Paler||(UK/Global)||+44 20 7604 8030|
||(UK/Global)||+44 20 7604 8037|
|Ayesha Bharmal||(UK/Global)||+44 20 7604 8034|
|Jacob Lund||(Sweden)||+46 8 553 260 20|
|Thomas Kudsk Larsen
||+44 20 7604 8199||mob: +44 7818 524185|
|Karl Hård||+44 20 7604 8123||mob: +44 7789 654364|
|Eugenia Litz||+44 20 7604 8233||mob: +44 7884 735627
|Anthony Brown||+44 20 7604 8067||mob: +44 7585 404943|
|Jens Lindberg||+44 20 7604 8414||mob: +44 7557 319729|
The information contained in this press release (the “Release”) is being provided by AstraZeneca PLC (the “Company” and, together with its subsidiaries, the “Group”). The Release is for information purposes only.
This Release is not a prospectus intended for potential investors and does not constitute or form part of and should not be construed as, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities to any person in any jurisdiction to whom or in which such offer or solicitation is unlawful nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with or act as any recommendation or inducement to enter into, any contract, commitment or investment decision whatsoever relating to any securities. Any purchase of securities in any proposed offering should be made solely on the basis of information contained in the base prospectus, as amended and supplemented from time to time, in respect of thereof.
This Release is only being provided to persons outside the United States in connection with offshore transactions in reliance on Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”). This Release and the information contained herein are not an offer of securities for sale in the United States. The securities proposed to be offered have not been, and will not be, registered under the Securities Act and, subject to certain exceptions, may not be offered or sold within the United States, its territories or possessions.
This Release is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of, or located in, any locality, state, country or other jurisdiction where such distribution or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.
This notice shall be governed by, and interpreted in accordance with, English law.
Confirmation of Understanding and Acceptance of Disclaimer
- I certify that I am not (nor do I act on behalf of someone who is) resident in any country that renders the accessing of this area of the website or parts thereof illegal.
- I represent and warrant to AstraZeneca that I intend to access this area of the website for information purposes only, that I have read and understood this notice and that I understand that it may affect my rights or responsibilities.
- I agree to be bound by the terms of this notice.